Literature DB >> 19212772

New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.

Karen D Wright1, Amar Gajjar.   

Abstract

INTRODUCTION: With the limited role of current treatment regimens and potential associated side effects of radiation in young children with ependymoma, considerable effort is being focused on new chemotherapeutic strategies and biologic agents. DISCUSSION AND
CONCLUSION: Identification of those molecular changes underlying the development of ependymoma may, in time, lead to the development of not only novel therapeutic agents, but also specific patient-tailored therapies directed against known cell-signaling pathways.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19212772      PMCID： PMC2738756          DOI： 10.1007/s00381-009-0809-7

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN： 0256-7040            Impact factor:   1.475


  79 in total

Review 1.  The role of pericytes in blood-vessel formation and maintenance.

Authors:  Gabriele Bergers; Steven Song
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

2.  Treatment with oral etoposide for childhood recurrent ependymomas.

Authors:  Alessandro Sandri; Maura Massimino; Luana Mastrodicasa; Nicola Sardi; Daniele Bertin; Maria Eleonora Basso; Liana Todisco; Alessandra Paglino; Giorgio Perilongo; Lorenzo Genitori; Laura Valentini; Umberto Ricardi; Lorenza Gandola; Felice Giangaspero; Enrico Madon
Journal:  J Pediatr Hematol Oncol       Date:  2005-09       Impact factor: 1.289

3.  A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors.

Authors:  B Horn; R Heideman; R Geyer; I Pollack; R Packer; J Goldwein; T Tomita; P Schomberg; J Ater; L Luchtman-Jones; K Rivlin; K Lamborn; M Prados; A Bollen; M Berger; G Dahl; E McNeil; K Patterson; D Shaw; M Kubalik; C Russo
Journal:  J Pediatr Hematol Oncol       Date:  1999 May-Jun       Impact factor: 1.289

4.  Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma.

Authors:  R J Gilbertson; S C Clifford; W MacMeekin; W Meekin; C Wright; R H Perry; P Kelly; A D Pearson; J Lunec
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

5.  Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children's Cancer Study Group (ANZCCSG).

Authors:  L White; S Kellie; E Gray; I Toogood; K Waters; L Lockwood; S Macfarlane; H Johnston
Journal:  J Pediatr Hematol Oncol       Date:  1998 Mar-Apr       Impact factor: 1.289

6.  Radial glia cells are candidate stem cells of ependymoma.

Authors:  Michael D Taylor; Helen Poppleton; Christine Fuller; Xiaoping Su; Yongxing Liu; Patricia Jensen; Susan Magdaleno; James Dalton; Christopher Calabrese; Julian Board; Tobey Macdonald; Jim Rutka; Abhijit Guha; Amar Gajjar; Tom Curran; Richard J Gilbertson
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

7.  Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group.

Authors:  P L Robertson; P M Zeltzer; J M Boyett; L B Rorke; J C Allen; J R Geyer; P Stanley; H Li; A L Albright; P McGuire-Cullen; J L Finlay; K R Stevens; J M Milstein; R J Packer; J Wisoff
Journal:  J Neurosurg       Date:  1998-04       Impact factor: 5.115

8.  Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.

Authors:  H Stacy Nicholson; Cynthia S Kretschmar; Mark Krailo; Mark Bernstein; Richard Kadota; Daniel Fort; Henry Friedman; Michael B Harris; Nicole Tedeschi-Blok; Claire Mazewski; Judith Sato; Gregory H Reaman
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

9.  Childhood intracranial ependymoma: twenty-year experience from a single institution.

Authors:  Hui-Kuo G Shu; Walter F Sall; Amit Maity; Zelig A Tochner; Anna J Janss; Jean B Belasco; Lucy B Rorke-Adams; Peter C Phillips; Leslie N Sutton; Michael J Fisher
Journal:  Cancer       Date:  2007-07-15       Impact factor: 6.860

10.  Metastatic ependymoma: a multi-institutional retrospective analysis of prognostic factors.

Authors:  Stergios Zacharoulis; Lingyun Ji; Ian F Pollack; Patricia Duffner; Russel Geyer; Jacques Grill; Steven Schild; Tang-Her Jaing; Maura Massimino; Jonathan Finlay; Richard Sposto
Journal:  Pediatr Blood Cancer       Date:  2008-02       Impact factor: 3.167
View more
  10 in total

Review 1.  Ependymomas in adults.

Authors:  Mark R Gilbert; Roberta Ruda; Riccardo Soffietti
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

2.  Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy.

Authors:  Su Guan; Ruijun Shen; Tiffany Lafortune; Ningyi Tiao; Peter Houghton; W K Alfred Yung; Dimpy Koul
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

3.  Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma.

Authors:  P Rajappa; J Krass; H A Riina; J A Boockvar; Jeffrey P Greenfield
Journal:  Interv Neuroradiol       Date:  2011-12-16       Impact factor: 1.610

Review 4.  Chromosomal anomalies and prognostic markers for intracranial and spinal ependymomas.

Authors:  Isaac Yang; Daniel T Nagasawa; Won Kim; Marko Spasic; Andy Trang; Daniel C Lu; Neil A Martin
Journal:  J Clin Neurosci       Date:  2012-04-18       Impact factor: 1.961

5.  The impact of recent vincristine on human hematopoietic progenitor cell collection in pediatric patients with central nervous system tumors.

Authors:  Laura Cooling; Melissa Bombery; Sandra Hoffmann; Robertson Davenport; Patricia Robertson; John E Levine
Journal:  Transfusion       Date:  2014-02-17       Impact factor: 3.157

6.  Ependymoma in children under the age of 3 years: a report from the Canadian Pediatric Brain Tumour Consortium.

Authors:  Eve Purdy; Donna L Johnston; Ute Bartels; Chris Fryer; Anne-Sophie Carret; Bruce Crooks; David D Eisenstat; Lucie Lafay-Cousin; Valerie Larouche; Beverly Wilson; Shayna Zelcer; Mariana Silva; Eric Bouffet; Daniel Keene; Douglas R Strother
Journal:  J Neurooncol       Date:  2014-02-16       Impact factor: 4.130

7.  Cerebellopontine angle ependymoma in a 2-year- old child.

Authors:  Pravin Salunke; Manish Sharma; Kirti Gupta; Priyamvadha Kovai; Ashish Aggarwal
Journal:  J Neurosci Rural Pract       Date:  2012-05

8.  Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death.

Authors:  Hazel A Rogers; John-Paul Kilday; Cerys Mayne; Jennifer Ward; Martyna Adamowicz-Brice; Ed C Schwalbe; Steven C Clifford; Beth Coyle; Richard G Grundy
Journal:  Acta Neuropathol       Date:  2011-11-23       Impact factor: 17.088

9.  Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.

Authors:  Johannes Gojo; Daniela Lötsch; Sabine Spiegl-Kreinecker; Kristian W Pajtler; Katharina Neumayer; Pia Korbel; Asuka Araki; Anita Brandstetter; Thomas Mohr; Volker Hovestadt; Lukas Chavez; Dominik Kirchhofer; Gerda Ricken; Harald Stefanits; Andrey Korshunov; Stefan M Pfister; Karin Dieckmann; Amedeo A Azizi; Thomas Czech; Martin Filipits; Marcel Kool; Andreas Peyrl; Irene Slavc; Walter Berger; Christine Haberler
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

10.  Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable polymer matrix.

Authors:  Cheryl V Rahman; Stuart J Smith; Paul S Morgan; Keith A Langmack; Phil A Clarke; Alison A Ritchie; Donald C Macarthur; Felicity R Rose; Kevin M Shakesheff; Richard G Grundy
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.